Results 161 to 170 of about 73,607 (303)
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Cardiovascularis szövődmények a JAK2 mutációval járó klonális myeloproliferatív eltérésekben
A JAK2 egy olyan onkogén, melynek aktivációja myeloproliferativ hematológiai kórképek mellett összefüggésbe hozható fokozott kardiovaszkuláris rizikóval is.
Magyar, Eszter
core
Allergy, EarlyView.Imaging mass cytometry shows lupus panniculitis lesions are dominated by cytotoxic and skin‐homing T cells with abundant macrophages and B‐cell aggregates. Spatial neighborhood analysis reveals organized leukocyte architecture, including B‐cell proximity to naïve T cells and M1 macrophages to cytotoxic T cells.
Milad Ameri +11 more
wiley +1 more source
Andrology, EarlyView.ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick +7 more
wiley +1 more source
Chromosomal rearrangements involving Janus kinase 2 (JAK2) are rare but recurrent findings in lymphoid or myeloid neoplasia. Detection of JAK2 fusion genes is important as patients with aberrantly activated JAK2 may benefit from treatment with tyrosine ...
Lazarevic, Vladimir +4 more
core +2 more sources
Annals of HematologyEosinophilia associated with PCM1::JAK2 fusion and classic Philadelphia (Ph)-negative myeloproliferative neoplasms (MPN) are both clonal disorders caused by a dysregulation of the JAK2 signaling pathway.
Oscar Borsani +3 more
doaj +1 more source
British Journal of Haematology, EarlyView.Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas +35 more
wiley +1 more source
British Journal of Haematology, EarlyView.Targeted next‐generation sequencing combined with a structured interpretative framework integrating gene–disease validity, population data, computational predictions, ACMG criteria and structural modelling enabled prioritisation of rare variants in idiopathic erythrocytosis, highlighting the genetic heterogeneity and biological complexity underlying ...
Alessandra Giannella +21 more
wiley +1 more source